SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy

Selim, Rania; Wellens, Judith; Marlow, Luke; Satsangi, Jack

doi:10.1016/s2468-1253(21)00347-2

Cited by 11 publications

(12 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The findings provide reassurance to patients with IBD and clinicians treating them regarding the seroconversion after complete vaccination for most vaccines. 61,62 The other important finding is the impact of drugs on seroconversion rates: the rates of seroconversion were statistically similar among various drugs. The pooled seroconversion rates were numerically lower for steroids and combination of anti-TNF with immunomodulator.…”

Section: Discussionmentioning

confidence: 95%

Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis

Jena

James

Singh

et al. 2022

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 95%

Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis

Jena

James

Singh

et al. 2022

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

“…A study in the United Kingdom also pointed to a higher level of vaccine hesitancy in younger age groups, highlighting the possibility that female patients of childbearing age may be hesitant about the vaccine. 21 Furthermore, larger studies on the long-term safety of the vaccine in diverse IBD populations are needed. Above all, vaccination rates in the IBD population need to be improved, especially in the younger age group on biologics.…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2-inactivated vaccine hesitancy and the safety in inflammatory bowel disease patients: a single-center study

Cao

Feng

Duan

et al. 2022

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine is thought to be the most effective preventive method of controlling the coronavirus disease 2019 (COVID-19) epidemic. Some patients with immune-related diseases, including inflammatory bowel disease (IBD) patients, however, may hesitate to be vaccinated for various reasons. Although several guidelines recommend vaccinating all IBD patients with inactivated SARS-CoV-2 vaccines, there is still a lack of real-world data on the safety of inactivated SARS-CoV-2 vaccines and COVID-19 vaccination rate in IBD patients. In this study, we investigated the reasons for hesitancy in COVID-19 vaccination, the COVID-19 vaccination rate, and the safety of SARS-CoV-2-inactivated vaccination in patients with IBD. Methods: This was a retrospective study. A total of 418 participants with IBD were enrolled to calculate the vaccination rates. A total of 232 patients with IBD who did not receive SARS-CoV-2 vaccination were recruited to investigate the reasons for hesitation. A follow-up survey of 151 IBD patients and 188 healthy participants who had received the SARS-CoV-2-inactivated vaccination was conducted to analyze adverse reactions. Results: The COVID-19 vaccination rate was 49.3% and almost half of the participants were ‘Concerned about the safety of the vaccine (such as adverse reactions) due to IBD’. After SARS-CoV-2 vaccination, adverse reactions were mild or moderate. The adverse reactions in the IBD and non-IBD populations were roughly the same, and IBD medications did not increase the risk of adverse reactions. Conclusion: SARS-CoV-2-inactivated vaccination rates in IBD patients are still low and a significant proportion of patients are hesitant about the vaccine because of safety concerns. SARS-CoV-2-inactivated vaccination in patients with IBD appears to be safe.

show abstract

“…Recent study before COVID-19 pandemic showed improving vaccination rate in IBD patients, and high uptake of COVID-19 vaccination in London. 2,3 However, global data for vaccine uptake is still not available.…”

Section: Rate Of Vaccination In Ibd Patientsmentioning

confidence: 99%

Vaccination for Inflammatory Bowel Disease Patients

Yunihastuti

2022

InaJGHE

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) patients have an increased rate of some vaccine-preventable infection during their course of disease. However, the coverage of vaccination is still low. Many physicians often do not feel comfortable or confidence offering vaccination to IBD patients. Vaccine effectiveness can be altered by the immune dysregulation condition and immunosuppressive therapy that IBD patients use. There are also some concerns about IBD flare after vaccination and potential adverse events related to live vaccines. Nonetheless, offering vaccines and obtaining vaccination history is necessary for health care maintenance of IBD patients, especially those using immunosuppressive therapy.

show abstract

SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy

Cited by 11 publications

References 4 publications

Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis

Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis

SARS-CoV-2-inactivated vaccine hesitancy and the safety in inflammatory bowel disease patients: a single-center study

Vaccination for Inflammatory Bowel Disease Patients

Contact Info

Product

Resources

About